XIUCAI LIU（刘修才）先生具备与其行使职权相适应的任职条件，其任职资 格符合《公司法》《上市规则》等有关法律、法规和规范性文件的规定，不存在 受到中国证券监督管理委员会、证券交易所处罚的情形。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》等法律、法规、规范性文件及《上 海凯赛生物技术股份有限公司章程》等有关规定，上海凯赛生物技术股份有限公 司（以下简称"公司"）于 2026 年 3 月 23 日召开第三届董事会第六次会议，聘 任公司首席科学家，即公司高级管理人员，现将相关情况公告如下： 2026 年 3 月 23 日，公司召开第三届董事会第六次会议，审议通过了《关于 聘任首席科学家的议案》，同意认定公司首席科学家为公司高级管理人员职务， 暨聘任公司首席科学家 XIUCAI LIU（刘修才）先生为公司高级管理人员 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2026-003 特别风险提示 公司及控股子公司开展外汇衍生品交易遵循合法、谨慎、安全和有效原则， 交易行为均以正常生产经营为基础，以规避和防范汇率风险为目的，不进行单纯 以盈利为目的的投机和套利交易。但业务操作仍可能存在一定风险，公司将严格 按照内控制度和风险控制措施审慎操作，防范相关风险。敬请广大投资者注意投 资风险。 上海凯赛生物技术股份有限公司 关于开展外汇套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易主要情况 | 交易目的 | □获取投资收益 套期保值（合约类别：□商品；外汇；□其他： | | --- | --- | | | ________） | | | □其他：________ | | 交易品种 | 外汇远期、外汇掉期、买入期权、卖出期权及期权组合等相 对简单透明、流动性强、风险可认知、市场有公开参考价格 | | | 的外汇衍生品 | | 交易金额 | 预计任一交易日持有的最高合 50,000（含等值其他货币） ...

中信证券股份有限公司 关于上海凯赛生物技术股份有限公司 开展外汇套期保值业务的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为上海凯 赛生物技术股份有限公司（以下简称"凯赛生物"或"公司"）持续督导的保荐 人，根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上 市规则》以及《科创板上市公司持续监管办法（试行）》等有关法律法规、规范 性文件的规定，对凯赛生物开展外汇套期保值业务的事项进行了审慎核查，核查 情况及核查意见如下： 一、交易情况概述 （一）交易目的 公司出口业务外汇结算比重较大，为有效规避外汇市场的风险，防范汇率大 幅波动对公司经营业绩带来的不确定性风险，提高外汇资金使用效率，合理降低 财务费用，公司及控股子公司拟与银行等金融机构开展外汇衍生品交易业务。公 司及控股子公司的外汇套期保值业务以正常生产经营为基础，以规避和防范汇率 风险为目的。 公司开展外汇套期保值业务均以正常的本外币收支业务为背景，以进出口业 务为依托，交易金额、交易期限与实际业务需求或者风险敞口相匹配，合理安排 使用资金，不会影响公司主营业务的发展。 （二）交易金额 公司及控股子公司将根据合同需要 ...

招商证券股份有限公司 关于上海凯赛生物技术股份有限公司 开展外汇套期保值业务的核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐人"）作为上海凯 赛生物技术股份有限公司（以下简称"凯赛生物"或"公司"）持续督导的保荐 人，根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上 市规则》以及《科创板上市公司持续监管办法（试行）》等有关法律法规、规范 性文件的规定，对凯赛生物开展外汇套期保值业务的事项进行了审慎核查，核查 一、交易情况概述 （一）交易目的 公司出口业务外汇结算比重较大，为有效规避外汇市场的风险，防范汇率大 幅波动对公司经营业绩带来的不确定性风险，提高外汇资金使用效率，合理降低 财务费用，公司及控股子公司拟与银行等金融机构开展外汇衍生品交易业务。公 司及控股子公司的外汇套期保值业务以正常生产经营为基础，以规避和防范汇率 风险为目的。 公司开展外汇套期保值业务均以正常的本外币收支业务为背景，以进出口业 务为依托，交易金额、交易期限与实际业务需求或者风险敞口相匹配，合理安排 使用资金，不会影响公司主营业务的发展。 （二）交易金额 公司及控股子公司拟开展总额度不超过 50,000 万 ...

上海凯赛生物技术股份有限公司 董事、高级管理人员薪酬管理制度 （2026年3月） 第一章 总则 第一条 为进一步完善公司董事、高级管理人员的薪酬管理，建立科学 有效的激励与约束机制，调动董事、高级管理人员的积极性和创造性，提高 企业经营效益和管理水平，确保公司发展战略目标的实现，根据国家法律、 法规的规定及《上海凯赛生物科技股份有限公司章程》(以下简称"《公司 章程》")，结合公司实际情况，制定本制度。 第二条 本制度所称董事包括公司非独立董事、独立董事以及职工代表 董事。 本制度所称高级管理人员是指公司总裁、副总裁、财务总监、董事会秘 书以及董事会认定的其他高级管理人员。 第三条 公司董事和高级管理人员的薪酬以公司经营与综合管理情况为 基础，根据经营计划完成情况、分管工作职责及工作目标完成情况、个人履 职及发展情况相结合进行综合考核确定薪酬。 第四条 公司董事和高级管理人员薪酬分配遵循以下基本原则： （一）公开、公平、公正的原则； （二）与公司实际经营情况及经营目标相结合的原则； （三）与公司长远利益相结合原则； （四）与责、权、利相匹配的原则； （五）激励约束并重原则。 第二章 管理机构 第五条 公司董事 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can drive industrial structure optimization and economic model transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper provides an overview of the development status and trends of biomanufacturing, analyzing the industry chain and key application directions [1]. - It compares the competitive landscape of biomanufacturing between China and the United States, identifying key differences and opportunities [7]. - Future development trends in biomanufacturing are discussed, indicating potential areas for growth and innovation [7]. Group 2: Policy Landscape - The report outlines major domestic and international policies affecting the biomanufacturing sector for 2024-2025, providing insights into regulatory environments [7]. - It details foreign policies that influence the global biomanufacturing industry, as well as domestic policies that shape the Chinese market [7]. Group 3: Industry Mapping and Key Players - The white paper identifies the "10 Leading Enterprises" in China's biomanufacturing industry, showcasing significant players and their contributions [7]. - It lists 15 publicly listed companies involved in synthetic biology, summarizing their strategic directions and investments in the field [7]. - The report highlights 20 popular products in the biomanufacturing space, linking them to corresponding companies [7]. Group 4: Challenges and Recommendations - The document discusses the challenges faced by China's biomanufacturing industry, including technological, regulatory, and market-related issues [7]. - It offers targeted policy recommendations to address these challenges, aiming to support the sustainable development of the biomanufacturing sector [7].

Core Viewpoint - The "2026 Advanced Nylon Industry Innovation and Application Development Conference" successfully gathered over 200 representatives from leading companies, experts, and end-users in the nylon industry, focusing on high-quality development paths for the nylon industry under the theme of "Big Materials, Big Markets, Big Changes" [2][6]. Group 1: Conference Overview - The conference was hosted by DT New Materials and supported by XPeng Motors, featuring over 20 thematic reports and activities aimed at exploring the innovative applications of nylon materials [2][6]. - Key topics included bio-based polyamides, special nylon innovations, and emerging application scenarios, emphasizing the importance of collaboration and innovation in the industry [6][9]. Group 2: Key Reports and Innovations - A report by Tang Zhaobin from the Ningbo Institute of Materials Technology and Engineering focused on the development of bio-based polyamides, highlighting the successful creation of high-temperature, transparent, and elastic nylon products with tensile strengths reaching 170 MPa and light transmittance over 90% [9]. - Li Shupeng from Guangzhou Automobile Group discussed the application of nylon engineering plastics in the new energy vehicle sector, outlining trends towards localization, low carbon emissions, and lightweight materials [11]. - Qin Huaili from Huitong New Materials emphasized the shift in the nylon industry from scale expansion to technology-driven, value-prioritized approaches, detailing a comprehensive product matrix from basic to high-end nylon materials [14]. Group 3: Market Trends and Applications - Reports highlighted the growing demand for special nylon materials in various sectors, including automotive, electronics, and consumer goods, with a focus on performance enhancements and sustainability [17][19][32]. - The application of MXD6 special nylon was analyzed, showcasing its core performance and potential in food packaging, automotive manufacturing, and high-end equipment [19][32]. - The conference also addressed the challenges and opportunities in the nylon industry, particularly in the context of energy system restructuring and trade environment adjustments [6][11]. Group 4: Future Directions - The conference concluded with discussions on the future of nylon materials, emphasizing the need for innovation in response to market demands and technological advancements [6][69]. - DT New Materials plans to continue facilitating industry collaboration through future events and conferences, focusing on new materials and technological innovations [69].

Core Viewpoint - The article discusses the advancements and applications of bio-based polyamides (Bio-PAs) produced through biomanufacturing, highlighting their environmental benefits and potential in various industries [2][3]. Group 1: Bio-Manufacturing and Bio-PAs - Biomanufacturing utilizes microorganisms, cells, and enzymes to produce various products, characterized by high efficiency, low energy consumption, and reduced greenhouse gas emissions [2]. - Bio-PAs are derived from renewable biomass and can achieve net-zero carbon emissions throughout their lifecycle due to the carbon dioxide absorption by plants during growth [2]. - Bio-PAs can be categorized into two types: AB type and AABB type, with PA11 being the most commercially mature product, produced by Arkema under the brand "Rilsan®" [2]. Group 2: Cathay Biotech Inc. - Cathay Biotech Inc. is a leading global company in the research and production of bio-based polyamide materials, offering products that match the performance of traditional polyamides while supporting sustainable development [3]. - The company’s products are applicable in various sectors, including new energy, transportation, construction, packaging, and electronics, contributing to industry transformation and carbon neutrality goals [3]. Group 3: Upcoming Conference - The "2026 Advanced Nylon Industry Innovation and Application Development Conference" will be held in Guangzhou on March 19-20, 2026, focusing on the latest advancements in nylon materials and their applications [6][13]. - The conference will feature discussions on nylon materials' needs in emerging applications such as humanoid robots and low-altitude economy, with participation from industry leaders and experts [8][13].

Core Viewpoint - The article emphasizes the significant advancements in synthetic biology and biomanufacturing in Shanghai, highlighting the city's role as a leading hub for innovation and commercialization in these fields [2][13]. Group 1: Policy and Industry Development - The National People's Congress has made biomanufacturing a key topic, with a focus on enhancing economic growth through sectors like quantum technology and synthetic biology [2]. - Shanghai is recognized as a national center for synthetic biology, hosting the first synthetic biology laboratory and the first listed synthetic biology company, Kasei Biotech [2]. - The "14th Five-Year Plan" aims to address common challenges in the industry, such as the "valley of death" in technology transfer and scaling up production [2][8]. Group 2: Technological Innovations - Synthetic biology is described as a transformative field that enables the engineering of microorganisms to produce pharmaceuticals, materials, and food products efficiently [3]. - Companies like Kasei Biotech and Changjin Biotech are leading innovations, producing bio-based products from renewable resources, including proteins and bioplastics [5][6]. - The development of cell-free protein synthesis technology is highlighted as a breakthrough, with companies like Kangma Biotech achieving large-scale production capabilities [6]. Group 3: Research and Infrastructure - The establishment of the Shanghai Synthetic Biology Innovation Center aims to facilitate the transition from laboratory research to market-ready products, providing funding and support for proof-of-concept projects [11][12]. - The article mentions the importance of foundational research, with significant achievements in synthetic biology, such as the creation of functional synthetic chromosomes [10]. - Shanghai's ecosystem is supported by a robust policy framework, including the "Action Plan for Accelerating Synthetic Biology Innovation" [14]. Group 4: Future Outlook - By the end of 2025, Shanghai is expected to have over 40 core synthetic biology enterprises, accounting for approximately 30% of the national total [7]. - The city aims to double the output value of biomanufactured products by 2030, with a focus on developing five core innovative capabilities [14]. - The article outlines Shanghai's strategy to create a replicable model for innovation, emphasizing collaboration with global research networks and attracting international resources [16].

Core Insights - The 11th Bio-based Conference and Exhibition will be held in Shanghai from May 20-22, focusing on bio-based chemicals and materials, featuring 11 thematic forums, 7 concurrent activities, and 1000 new product displays [2] Group 1: Company Overview - Kasei Biotech, established in 2000, focuses on synthetic biology and bio-manufacturing technology, becoming a global leader in producing new bio-based materials [3] - Kasei Biotech's revenue for 2025 is projected to reach 3.295 billion yuan, marking an 11.41% increase, with a net profit of 566 million yuan, up 15.7% [3] - Huaheng Biotech, founded in 2005, plans to list in Hong Kong and expects a revenue of 2.885 billion yuan in 2025, a 32.5% increase, but a net profit decrease of approximately 30% [9][10] - Huadong Medicine achieved a revenue of 41.906 billion yuan in 2024, a 3.16% increase, with a net profit of 3.512 billion yuan, up 23.72% [14] Group 2: Main Business Composition - Kasei Biotech's main revenue sources include long-chain dicarboxylic acids (2.67 billion yuan, 90.26% of revenue) and bio-based polyamides (144 million yuan, 4.88% of revenue) [6] - Huaheng Biotech's main products include amino acids (1.509 billion yuan, 69.29% of revenue) and vitamins (207 million yuan, 9.49% of revenue) [10] - Huadong Medicine's industrial microbiology segment saw revenue growth from 510 million yuan in 2022 to 711 million yuan in 2024, with a CAGR of 18.07% [14] Group 3: Research and Development Projects - Kasei Biotech is investing in projects like bio-manufacturing research with a total investment of 6.3 million yuan, focusing on fermentation and extraction technology [7] - Huaheng Biotech has multiple ongoing projects, including optimizing amino acid production strains and developing high-purity amino acid removal processes [11][12] - Huadong Medicine has initiated 393 research projects in industrial microbiology, focusing on xRNA raw materials and health-related products [18] Group 4: Development Strategies - Kasei Biotech aims to expand large-scale applications of bio-materials to replace petrochemical products and utilize agricultural waste for bio-manufacturing [8] - Huaheng Biotech focuses on becoming a leader in synthetic biology through innovation and collaboration, emphasizing the use of renewable resources [13] - Huadong Medicine is accelerating its business layout through cooperation and acquisitions, focusing on xRNA raw materials and health products [25] Group 5: Financial Performance - Kasei Biotech's revenue for 2025 is projected to be 3.295 billion yuan, with a net profit of 566 million yuan [3] - Huaheng Biotech expects a revenue of 2.885 billion yuan in 2025, with a significant decrease in net profit [9] - Huadong Medicine's revenue reached 41.906 billion yuan in 2024, with a notable increase in net profit [14] Group 6: Market Trends - The bio-based industry is witnessing a shift towards sustainable materials, with companies focusing on reducing reliance on fossil fuels and enhancing the use of agricultural by-products [8][13] - The demand for bio-based products is expected to grow, driven by environmental concerns and regulatory support for sustainable practices [2][8]